Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ATRC 
AtriCure Inc (ATRC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: ATRC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $50
1 Year Target Price $50
| 5 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.78% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.85B USD | Price to earnings Ratio - | 1Y Target Price 50 |
Price to earnings Ratio - | 1Y Target Price 50 | ||
Volume (30-day avg) 9 | Beta 1.59 | 52 Weeks Range 27.64 - 43.11 | Updated Date 10/17/2025 |
52 Weeks Range 27.64 - 43.11 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.27% | Operating Margin (TTM) -4.55% |
Management Effectiveness
Return on Assets (TTM) -3.53% | Return on Equity (TTM) -7.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1663716520 | Price to Sales(TTM) 3.69 |
Enterprise Value 1663716520 | Price to Sales(TTM) 3.69 | ||
Enterprise Value to Revenue 3.33 | Enterprise Value to EBITDA -135.97 | Shares Outstanding 49701415 | Shares Floating 47934033 |
Shares Outstanding 49701415 | Shares Floating 47934033 | ||
Percent Insiders 3.23 | Percent Institutions 100.83 |
Upturn AI SWOT
AtriCure Inc
Company Overview
History and Background
AtriCure, Inc. was founded in 2000. It is a medical device company focused on developing and marketing innovative solutions for the treatment of atrial fibrillation (Afib) and related conditions.
Core Business Areas
- Atrial Fibrillation Therapy: Develops and markets surgical ablation systems and related products for the treatment of atrial fibrillation. These products are used to create lesions in the heart tissue to block abnormal electrical signals that cause Afib.
- Left Atrial Appendage Management: Offers products for the exclusion of the left atrial appendage (LAA), a pouch-like structure in the heart where blood clots can form in patients with Afib. These products help reduce the risk of stroke.
Leadership and Structure
Michael Carrel is the CEO. The company has a board of directors and operates through various departments including R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- CryoICE Cryoablation System: This system uses cryoenergy to ablate cardiac tissue. Used during open surgical procedures. Competitors include Medtronic and Boston Scientific. Estimated market share for cryoablation is around 20-25% overall in cardiac surgery.
- AtriClip Left Atrial Appendage Exclusion System: A clip-like device used to surgically occlude the left atrial appendage. Used during both open and minimally invasive procedures. Competitors include Abbott (with their Watchman device via percutaneous approach). AtriCure has a significant share in surgical LAA management.
- Epi-Sense Ablation System: A bipolar radiofrequency ablation system used to create lesions on the epicardial surface of the heart. This allows electrophysiologists to perform surgical ablation. Competitors include Medtronic.
Market Dynamics
Industry Overview
The electrophysiology and cardiac surgery market is experiencing growth due to the increasing prevalence of atrial fibrillation and advancements in treatment technologies.
Positioning
AtriCure is a leading player in surgical ablation and LAA management, with a focus on innovative technologies and minimally invasive approaches.
Total Addressable Market (TAM)
The estimated TAM for atrial fibrillation treatment is in the billions of dollars annually. AtriCure is positioned to capture a significant portion of this market through its comprehensive product portfolio.
Upturn SWOT Analysis
Strengths
- Strong product portfolio focused on Afib treatment
- Established brand recognition and reputation in surgical ablation
- Focus on innovation and technology leadership
- Experienced management team
Weaknesses
- Reliance on surgical procedures which may face competition from catheter-based approaches
- Limited geographic diversification compared to larger competitors
- Reimbursement pressures in healthcare industry
- Smaller market capitalization than major competitors
Opportunities
- Expanding into new geographic markets
- Developing new products and technologies for Afib treatment
- Increasing adoption of minimally invasive surgical techniques
- Partnerships with hospitals and healthcare providers
Threats
- Competition from larger medical device companies
- Technological advancements that could render existing products obsolete
- Changes in healthcare regulations and reimbursement policies
- Economic downturns that could reduce healthcare spending
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
Competitive Landscape
AtriCure competes with larger medical device companies in the Afib treatment market. It differentiates itself through its focus on surgical ablation and LAA management, as well as innovation in minimally invasive techniques. Its size is a disadvantage compared to Medtronic, Abbott, and Boston Scientific.
Major Acquisitions
SentreHEART, Inc.
- Year: 2021
- Acquisition Price (USD millions): 300
- Strategic Rationale: Expanded AtriCure's portfolio to include percutaneous left atrial appendage closure technology.
Growth Trajectory and Initiatives
Historical Growth: AtriCure has demonstrated historical growth in revenue driven by adoption of its surgical ablation and LAA management products.
Future Projections: Future growth is expected to be driven by increasing prevalence of Afib, expanding market penetration, and new product launches. Analyst estimates need to be added here when provided.
Recent Initiatives: Recent initiatives include expanding the AtriClip portfolio and continued R&D investments.
Summary
AtriCure is a strong player in the surgical Afib and LAA management market due to their innovativeness in products. Their innovation is allowing growth in these markets, however, they should look out for competition from larger companies like Medtronic and Abbott that have a larger reach and more resources. A risk to their business model is that they rely heavily on surgical procedures that will become less attractive if catheter-based procedures become cheaper.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered as financial advice. Investment decisions should be made based on individual risk tolerance and after consulting with a qualified financial advisor. Market share percentages are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AtriCure Inc
Exchange NASDAQ | Headquaters Mason, OH, United States | ||
IPO Launch date 2005-08-05 | CEO, President & Director Mr. Michael H. Carrel | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1300 | Website https://www.atricure.com |
Full time employees 1300 | Website https://www.atricure.com | ||
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.